ICCC

Healthcare Biotechnology

ImmuCell Corporation

$9.73
+0.01 +0.05% today Live

Price History

Not enough data
Price chart data
DatePrice
Oct 5, 2026, live at 12:04 PM ET9.73

Key Stats

Market Cap
88.42M
Avg Volume
24,223
P/E (TTM)
139.07
EPS
$0.07
52W High
$12.10
52W Low
$4.52
Div. Yield
0.0%

Valuation

Forward P/E
-88.50
P/B Ratio
2.82
P/S Ratio
2.88
EV/EBITDA
13.07
EV/Revenue
3.00

Margins

Gross Margin 40.3%
Operating Margin 26.9%
Net Margin 2.6%
EBITDA Margin 23.0%

Growth & Returns

Revenue Growth (YoY)
11.5%
Earnings Growth (YoY)
259.9%
Earnings Growth (QoQ)
265.6%
Return on Equity
2.6%
Return on Assets
6.2%

Liquidity & Leverage

Current Ratio
4.75
Quick Ratio
2.65
Debt / Equity
0.40
Total Cash
8.86M
Total Debt
12.45M

About

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

immucell.com